Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Manmeet Ahluwalia MD, FACP, MBA

Manmeet Ahluwalia MD, FACP, MBA

Deputy Director, Chief of Medical Oncology, and Chief Scientific Officer, Miami Cancer Institute, Miami, Florida

Dr. Manmeet Ahluwalia is the Chief Scientific Officer, Chief of Medical Oncology, and Deputy Director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute. Previously, he was the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC), Cleveland Clinic, Ohio, where he subspecialized in treatment of patients with brain tumors and brain metastases. He was also a Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

A neuro-oncologist, Dr. Ahluwalia's research focuses on the development of new therapies for patients with brain tumors and brain metastases. He is currently leading several clinical trials involving new targeted therapies as well as immunotherapeutic approaches. His research has been presented nationally and internationally and has resulted in over 175 editorials, peer-reviewed manuscripts, and book chapters.

Recent Contributions to PracticeUpdate:

  1. Impact of Steroids on Efficacy of Immunotherapy for Patients With NSCLC Brain Metastases
  2. Treatment of Brain Metastases With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors
  3. Limited Clinical Benefit of PD-1 Inhibition in Patients With Recurrent High-Grade Glioma
  4. EGFR Inhibitors for CNS Metastases From NSCLC
  5. ASCO 2018: Antibody-Drug Conjugate Shows Promise in Glioblastoma
  6. ASCO 2018: Advances and Future Directions for Vaccines for Glioblastoma
  7. ASCO 2018: Abstract Recommendations From Dr. Manmeet Ahluwalia
  8. New Developments in the Management of Brain Metastases
  9. Development of Brain Metastases in Patients With Renal Cell Carcinoma
  10. New Data on the Management of Recurrent GBM From SNO 2017: Practical Implications

Most Read This Week

Recently Updated